Highest-materiality recent filing
Journey Medical Q2 revenue up 23% to $18.5M; net loss narrows to $0.3M
Total revenues $18.5M for Q2 2026, +23% from $15.0M in Q2 2025; Emrosi sales $8.1M.
Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M
Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.
Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.
Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M
Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.
Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%
Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.
Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter
Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.
Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway
Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.
Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway
Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.
Journey Medical launches Emrosi for rosacea; first prescriptions filled
Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.
Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea
FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.
FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged
FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.
Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4
Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.
Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024
Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.
Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M
Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.
Entered into credit facility with SWK Funding LLC for up to $20M; initial draw of $15M on Dec 27, 2023.
GAAP net income $16.8M ($0.80 diluted) vs GAAP net loss $10.1M in Q3 2022.
Journey Medical regains Nasdaq compliance with stockholders' equity rule
Previously notified Aug 15, 2023 of non-compliance with Nasdaq minimum $2.5M stockholders' equity.
Journey Medical regains Nasdaq equity compliance after $19M Maruho license
Previously disclosed Nasdaq Staff notified Company of non-compliance with $2.5M stockholders' equity requirement on August 15, 2023.
Journey Medical licenses Qbrexza to Maruho for Asia; $19M upfront payment
Journey receives $19M non-refundable upfront payment from Maruho within 10 days of signing.
Journey Medical receives Nasdaq deficiency notice for stockholders' equity below $2.5M threshold
Nasdaq notified Journey Medical on Aug 15, 2023 of non-compliance with Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity; company reported equity of $5,000 as of June 30, 2023.
Journey Medical Q2 net loss $8.4M, revenue $17.2M; DFD-29 Phase 3 positive, NDA submission H2 2023
Q2 2023 net revenues $17.2M, down 6% YoY but up 41% QoQ; core product revenue grew 19% YoY to $15.6M (92% of total).
Journey Medical repays ~$10M debt to East West Bank, terminating credit agreement
Repaid approximately $10 million principal plus accrued interest and fees under EWB Credit Agreement.
Journey Medical Q1 net loss $10.1M on revenue decline; DFD-29 topline expected June 2023
Net product revenue $12.2M, down from $20.8M YoY, due to higher gross-to-net adjustments and lower Qbrexza, Targadox, Ximino sales.
Journey Medical CFO resigns; Corporate Controller Benesch named interim CFO effective Jan 27.
Ernest De Paolantonio resigns as CFO effective Jan 27, 2023; will consult through March 31, 2023.
Journey Medical Q3 revenue down 18% to $16.1M; net loss $10.1M; DFD-29 Phase 3 75% enrolled
Revenue $16.1M in Q3 2022 versus $19.6M in Q3 2021, decline due to Targadox generic competition.
Journey Medical Q2 net revenue up 20% to $18.3M; loss narrows to $7.5M
Net revenue $18.3M (+20% YoY), driven by new product launches despite Targadox generic competition.
Journey Medical reports record Q1 revenue of $23.3M, up 117% YoY; net loss of $1.4M
Record net product revenue $20.8M (+94% YoY); $2.5M milestone from Maruho for QBREXZA Japan approval.
Journey Medical reports FY2021 record revenue of $63.1M, net loss of $44.0M; DFD-29 Phase 3 underway
Record net product revenues of $63.1M in FY2021, up 42% from $44.5M in FY2020.
Journey Medical acquires VYNE's MST franchise for $20M upfront; credit facility expanded to $30M
Acquired AMZEEQ, ZILXI, FCD105, and MST platform for $20M upfront plus $5M at one year; contingent milestones up to $450M.
Journey Medical Q3 2021 net revenue $19.6M (+108% YoY); non-GAAP net income $3.5M
Net revenue $19.6M vs $9.4M in Q3 2020, up 108%.
Underwriting agreement with B. Riley Securities for 3,520,000 shares of common stock at $10.00 per share.
On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.
appointed Michael C. Pearce, age 62, to serve on the Board
On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.
On December 7, 2023, Dr. Jeffrey Paley submitted his resignation from his position as a member of the Board of Directors (the “Board”) of Journey Medical Corporation (the “Company”), effective immediately.
On January 16, 2023, Ernest De Paolantonio, the Chief Financial Officer of Journey Medical Corporation (the “ Company ”) provided notice to the Company of his resignation, effective January 27, 2023.
Joseph Benesch, age 56, the Company’s Corporate Controller, was appointed as the Company’s interim Chief Financial Officer, effective January 27, 2023.
Max materiality 0.90 · Median 0.65 · Most common event earnings